ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above Two Hundred Day Moving Average of $5.00

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.00 and traded as high as $5.17. ProPhase Labs shares last traded at $4.90, with a volume of 62,087 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Stock Down 6.8 %

The stock has a market cap of $88.45 million, a price-to-earnings ratio of -5.00 and a beta of -0.29. The company has a current ratio of 2.28, a quick ratio of 2.10 and a debt-to-equity ratio of 0.29. The firm’s 50 day moving average is $5.53 and its two-hundred day moving average is $5.00.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $3.50 million for the quarter, compared to analysts’ expectations of $10.71 million. ProPhase Labs had a negative return on equity of 29.83% and a negative net margin of 37.81%. On average, sell-side analysts predict that ProPhase Labs, Inc. will post -0.88 EPS for the current year.

Hedge Funds Weigh In On ProPhase Labs

Several large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in ProPhase Labs by 50.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after purchasing an additional 5,026 shares in the last quarter. SVB Wealth LLC purchased a new position in ProPhase Labs in the 3rd quarter worth approximately $208,000. Finally, HighTower Advisors LLC acquired a new stake in ProPhase Labs in the third quarter valued at approximately $756,000. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.